Evidence map›Paper›PMID 22127699›Full record

ArticleArthritis and rheumatism2011

Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response.

Ling Zeng, Mary J Lindstrom, Judith A Smith

Abstract read
In one paragraph

Article in Arthritis and rheumatism, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 115 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Interpreting the Function of the IL-23/IL-17 Axis through Bioinformatics.Endocrine, metabolic & immune disorders drug targets · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Spondyloarthritides: Theories and beyond.Frontiers in pediatrics · 2022
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ling ZengUniversity of Wisconsin Madison, School of Medicine and Public Health, Madison, WI 53792-4108, USA.
Mary J Lindstrom
Judith A Smith
University of Wisconsin–Madison · US

Funding

INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
Regulation of IFN-beta induction by P2X7 purinergic receptor signalingK08AI081045 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI SMITH, JUDITH ANNE · 2009 to 2011
$419k
IMAGE PROCESSING CYTOMETERS10RR002501 · NCRR · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI MAYALL, BRIAN H · 1985 to 1985
–
NCRR NIH HHS 1UL1RR02501NCRR NIH HHS 1UL1RR025011NCRR NIH HHS UL1 RR025011NIAID NIH HHS AI081045NIAID NIH HHS K08 AI081045
6 · The paper itself

Abstract

objectivePrevious studies of the HLA-B27-transgenic rat model of ankylosing spondylitis (AS) suggested that macrophages develop an intracellular stress response called the unfolded protein response (UPR) and, as a result, secrete increased amounts of cytokines in response to Toll-like receptor agonists such as lipopolysaccharide (LPS). Our objective was to determine whether macrophages from AS patients also undergo a UPR and secrete increased cytokines/chemokines in response to LPS.

methodsPeripheral blood monocytes isolated from 10 AS patients and 10 healthy controls were differentiated in vitro with macrophage colony-stimulating factor. Select samples were treated with interferon-γ (IFNγ) to up-regulate class I major histocompatibility complex (HLA-B) expression prior to stimulation with LPS for either 3 hours (for RNA) or 8-24 hours (for supernatant). UPR induction was assessed by measuring the expression of messenger RNA for ERdj4, BiP, and CCAAT/enhancer binding protein homologous protein 10 (CHOP).

resultsAlthough IFNγ treatment up-regulated HLA-B expression (2-fold; P < 0.0001), neither IFNγ nor LPS substantially enhanced BiP or CHOP expression (<1.3-fold). ERdj4 expression increased weakly, but not significantly, in AS samples treated with IFNγ plus LPS (2.2-fold; P = 0.31). In response to LPS, AS macrophages secreted more CXCL9, interleukin-10 (IL-10), IL-12p70, IL-23, and tumor necrosis factor α than did control macrophages (P ≤ 0.025). The most striking difference was observed for IL-23 (median 265 pg/ml in AS patients versus 9 pg/ml in controls; P = 0.0007). We did not detect significant differences in IL-6, IL-8, or IFNβ production.

conclusionThe greater production of IL-23 by AS patient macrophages in response to LPS provides further support for the development of Th17/IL-23-directed therapy. Since significant UPR induction was not detected in AS patient macrophages, the relationship between UPR and inflammatory cytokine production remains unclear.

Indexed as

AdolescentAdultCase-Control StudiesCCAAT-Enhancer-Binding ProteinsCells, CulturedChemokinesCytokinesFemaleHLA-B AntigensHumansInterferon-gammaInterleukin-23LipopolysaccharidesMacrophagesMaleMiddle AgedBax-inhibiting peptide, BIPCCAAT-Enhancer-Binding ProteinsChemokinesCytokinesDDIT3 protein, humanHLA-B AntigensInterferon-gammaInterleukin-23LipopolysaccharidesOligopeptidesTranscription Factor CHOP

Identifiers

PMID22127699
PMCPMC3228355
OpenAlexW1991099151

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.